F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds

Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.

AI Summary: New in‑depth analyses of internal FDA documents reveal that regulatory decisions on the abortion pill mifepristone were firmly based on thorough evidence rather than political pressure, dispelling common misconceptions about politicized review processes.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days

FDA loosens data restrictions to accelerate drug reviews / 5 months

FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 6 months

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA approves leucovorin for rare folate disorder despite autism hype / 2 months

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months